Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

well-tolerated and may represent a benefit for patients in terms of convenience and ease of administration. Tanespimycin is clearly an active and manageable agent and is deserving of further clinical study."

"We continue to see meaningful antitumor activity and tolerability with the tanespimycin plus bortezomib combination in multiple myeloma across patient populations. In addition, we are observing intriguing evidence supporting the hypothesis that in the tanespimycin/bortezomib combination, tanespimycin may be exerting a neuroprotective effect based on the observation of reduced neuropathy, a side effect associated with bortezomib," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "The data from this ongoing trial are still being evaluated, and multiple patients remain on study. At this time, the overall response rate appears to be lower than previously reported. We are investigating whether there were patient characteristics that may have contributed to this lower response rate, including the possibility that patients added to the study since the data were last reported represented a more advanced and heavily pretreated population. We will complete the study and further evaluate the data in consultation with multiple myeloma experts to confirm the most expeditious course forward. Taken as a whole, the currently available data from this trial suggest that there may be utility in adjusting the TIME program to optimize the therapeutic potential of the tanespimycin and bortezomib combination. We have not, however, made any definitive decisions concerning a potential adjustment."

Tanespimycin Phase 1b Trial Results

The objective of the Phase 1b dose-escalating trial was to evaluate tanespimycin with bortezomib in patients with relapsed, refractory multiple myeloma, relative to safety, pharmacokinetic, pharmacodynamic and anti-myeloma effects. Dose escalations in the entire trial ranged from 100-340 mg/m2 for
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Colo. , July 6, 2015 ... encorafenib, was showcased this past weekend at the ... an oral presentation.  At the meeting, data were ... data from a 100-patient randomized Phase 2 expansion ... and cetuximab, an EGFR inhibitor, with or without ...
(Date:7/6/2015)... July 6, 2015 Akcea Therapeutics, a ... ISIS ), announced today that the U.S. Food ... to volanesorsen (ISIS-APOCIII Rx ) for the treatment ... is a rare genetic disease characterized by extremely ... a Phase 2 study published in the NEJM ...
(Date:7/4/2015)... , España, July 4, 2015 ... a la quimioterapia de primera línea para pacientes ... hígado (mCRC) extiende la supervivencia libre de progresión ... cáncer colorrectal metastásico no resecable (mCRC) que se ... mejora en la supervivencia libre de progresión (PFS) ...
Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5
... SAN DIEGO, Sept. 30 Cadence Pharmaceuticals, Inc. (Nasdaq: ... developing and commercializing proprietary product candidates principally for use ... host a live webcast of its Analyst Day on ... Cadence,s senior management team, led by Ted Schroeder, ...
... Sept. 30 Fifty-nine percent ... by general practitioners, according to a research report published ... study, conducted by researchers from Thomson Reuters and the ... analyzed prescribing patterns for psychotropic drugs from August 2006 ...
Cached Medicine Technology:Cadence Pharmaceuticals to Webcast October 7th Analyst Day 2Cadence Pharmaceuticals to Webcast October 7th Analyst Day 3General Practitioners Write Most Prescriptions for Mental Health Drugs, According to Study from Thomson Reuters and SAMHSA 2
(Date:7/6/2015)... ... July 06, 2015 , ... The School of ... to support a three-year effort to reduce rates of diabetes and cardiovascular disease ... partnership with the Morehouse School of Medicine’s Prevention Research Center and the Satcher ...
(Date:7/6/2015)... ... ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable to his ... to dissolve fat cells and is the first of its kind to be approved ... known as a double chin. Dr. Green participated in clinical trials for Kybella and ...
(Date:7/6/2015)... News, VA (PRWEB) , ... July 06, 2015 ... ... today that Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® ... Secours Mary Immaculate Hospital in Newport News, VA. The procedure was an L5-S1 ...
(Date:7/6/2015)... ... July 06, 2015 , ... Thanks to donations and a generous grant ... Music & Memory Certification for hospice patients and adult day center participants. , The ... to patients but also to their families and volunteers. Music & Memory is a ...
(Date:7/5/2015)... MN (PRWEB) , ... July 06, 2015 , ... ... the ancillary benefits market, is excited to announce the next generation of PrimeStar ... and Advantage plans to now include two network options—Maximum Allowable Charge (MAC) and ...
Breaking Medicine News(10 mins):Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... more than 25 countries will converge on Boston ... 2008 Annual,Conference & Exhibition. The annual event is ... in the healthcare product sector., The regulatory ... job responsibilities related to ensuring that healthcare,products in ...
... become a "difficult patient" before she could get her physicians ... , And once the diagnosis was made, she had to ... she could get the best treatment for scleroderma, a chronic ... major element. , Mayer, a research assistant professor of health ...
... Clinics of Georgia is proud to announce Dr. Chad Levitt, a ... RCOG,s Cumming, GA. Dr. Levitt specializes in head & neck, breast, ... ... Atlanta, GA. (PRWEB) September 10, 2008 -- Board Certified Radiation Oncologist ...
... specializing in risk assessment for diabetics, recently announced that The Hope ... provide retinal imaging risk assessment. , ... Wake Forest, ... Healthcare, a Wake Forest, NC company specializing in risk assessment for ...
... Steve Poizner Will Present Keynote Address at the 6th Annual California ... event is open to the public and brings together over 500 ... lively discussion, and networking. , ... Huntington Beach, CA ...
... BOSTON, Mass. (Sep. 10, 2008)In recent years, private ... investment opportunities. Spurred by investigative reports and anecdotal ... of care, many companies have found themselves under ... a new study, such conclusions may be premature. ...
Cached Medicine News:Health News:Healthcare Product Regulatory Professionals to Convene in Boston for RAPS Annual Conference & Exhibition 2Health News:Healthcare Product Regulatory Professionals to Convene in Boston for RAPS Annual Conference & Exhibition 3Health News:Survival instincts propel 'difficult patient' to insist on quality care 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 3Health News:Dr. Chad Levitt Joins North Georgia Radiation Oncology Center 2Health News:Dr. Chad Levitt Joins North Georgia Radiation Oncology Center 3Health News:The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients 2Health News:Council on Education in Management Announces Insurance Commissioner Steve Poizner Will Present Keynote Address at the 6th Annual California Workers' Comp Forum 2Health News:Private equity companies purchase nursing homes, but care does not suffer 2Health News:Private equity companies purchase nursing homes, but care does not suffer 3
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
The MICROsed-System is the ideal system back up support to be used as front-line instrument with small workloads....
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: